Table 4.

Preference weights for vaccine acceptance, 7–30 June 2023, Guadeloupe

	Non-uniforms respondents (N = 111)			Non-uniform female respondents (N = 104)			Non-uniform respondents reporting a child not vaccinated against HPV and reporting no intention to vaccinate (N = 43)
Attributes and levels	Odds Ratio	[95% confidence interval]		Odds Ratio	[95% confidence interval]		Odds Ratio	[95% confidence interval]
Disease characteristics
Genital and oral warts	Ref			Ref			Ref
Cancer prevention	1.30	0.84	2.01	1.23	0.78	1.92	1.20	0.61	2.36
Prevention of pregnancy complications	0.72	0.48	1.07	0.76	0.50	1.15	0.84	0.45	1.59
Sexual discomfort	0.79	0.50	1.24	0.72	0.45	1.14	0.64	0.31	1.31
Vaccine safety
No side effects	Ref			Ref			Ref
Long term observation	1.28	0.80	2.04	1.35	0.83	2.19	0.90	0.44	1.85
WHO: vaccine effective and safe	0.69	0.45	1.07	0.65	0.41	1.02	0.51	0.25	1.02
Favorable risk–benefit balance	0.80	0.52	1.24	0.82	0.52	1.27	1.00	0.50	2.01
Recommendation sources
Ministry of Health and regional health authority	Ref			Ref			Ref
School health and maternal and Child welfare services	1.03	0.69	1.52	1.02	0.68	1.54	0.73	0.39	1.34
General practitioner	0.92	0.64	1.34	0.92	0.63	1.36	0.65	0.36	1.17
Social conformity
Low vaccination coverage in adolescents (15%)	Ref			Ref			Ref
High vaccination coverage in adolescents (70%)	1.76	1.18	2.63	1.81	1.19	2.73	1.28	0.68	2.44
High vaccination coverage in adolescents (> 70%) in Puerto Rico and Canada	2.00	1.34	2.99	2.09	1.38	3.17	1.60	0.84	3.03
Optimal age
Vaccine effective at all ages	Ref			Ref			Ref
Vaccine more effective before 14 years: optimal antibody production	1.87	1.26	2.77	1.80	1.20	2.69	3.21	1.70	6.07
Vaccine more effective before sexual debut	1.38	0.95	2.00	1.27	0.87	1.86	1.17	0.65	2.10